The price of Apellis Pharmaceuticals Inc (NASDAQ:APLS) shares last traded on Wall Street fell -1.70% to $28.08.
APLS stock price is now -11.14% away from the 50-day moving average and -37.02% away from the 200-day moving average. The market capitalization of the company currently stands at $3.42B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $25, RBC Capital Mkts recently initiated with Sector Perform rating for Apellis Pharmaceuticals Inc (NASDAQ: APLS). , while ‘Scotiabank’ rates the stock as ‘Sector Outperform’
In other news, Dunlop A. Sinclair, Director sold 37,000 shares of the company’s stock on Sep 16 ’24. The stock was sold for $1,340,597 at an average price of $36.23. Upon completion of the transaction, the Director now directly owns 100,000 shares in the company, valued at $2.81 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 16 ’24, VP/Chief Accounting Officer Chopas James George sold 192 shares of the business’s stock. A total of $6,952 was realized by selling the stock at an average price of $36.21. This leaves the insider owning 38,141 shares of the company worth $1.07 million. A total of 17.07% of the company’s stock is owned by insiders.
During the past 12 months, Apellis Pharmaceuticals Inc has had a low of $26.28 and a high of $73.80. As of last week, the company has a debt-to-equity ratio of 1.80, a current ratio of 5.08, and a quick ratio of 4.18. The fifty day moving average price for APLS is $31.8299 and a two-hundred day moving average price translates $44.761074 for the stock.
The latest earnings results from Apellis Pharmaceuticals Inc (NASDAQ: APLS) was released for 2024-06-30. The net profit margin was -52.94% and return on equity was -109.19% for APLS. The company reported revenue of $199.69 million for the quarter, compared to $94.97 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 110.26 percent.
